HK1166978A1 - 噁二唑衍生物配體及其作為親代謝性谷氨酸受體 增效劑的用途 - Google Patents

噁二唑衍生物配體及其作為親代謝性谷氨酸受體 增效劑的用途

Info

Publication number
HK1166978A1
HK1166978A1 HK12106999.4A HK12106999A HK1166978A1 HK 1166978 A1 HK1166978 A1 HK 1166978A1 HK 12106999 A HK12106999 A HK 12106999A HK 1166978 A1 HK1166978 A1 HK 1166978A1
Authority
HK
Hong Kong
Prior art keywords
potentiators
glutamate receptor
metabotropic glutamate
oxadiazole derivatives
oxadiazole
Prior art date
Application number
HK12106999.4A
Other languages
English (en)
Inventor
Joshua Clayton
Ian Egle
James Empfield
James Folmer
Methvin Isaac
Fupeng Ma
Abdelmalik Slassi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40093925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1166978(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1166978A1 publication Critical patent/HK1166978A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
HK12106999.4A 2007-06-07 2010-09-15 噁二唑衍生物配體及其作為親代謝性谷氨酸受體 增效劑的用途 HK1166978A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94255307P 2007-06-07 2007-06-07

Publications (1)

Publication Number Publication Date
HK1166978A1 true HK1166978A1 (zh) 2012-11-16

Family

ID=40093925

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10108742.2A HK1142318A1 (en) 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842
HK12106999.4A HK1166978A1 (zh) 2007-06-07 2010-09-15 噁二唑衍生物配體及其作為親代謝性谷氨酸受體 增效劑的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK10108742.2A HK1142318A1 (en) 2007-06-07 2010-09-15 Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842

Country Status (34)

Country Link
US (2) US8377940B2 (zh)
EP (2) EP2167502B3 (zh)
JP (2) JP5416696B2 (zh)
KR (2) KR20100017640A (zh)
CN (2) CN102977086B (zh)
AR (1) AR066882A1 (zh)
AU (1) AU2008260717B2 (zh)
BR (1) BRPI0812889A2 (zh)
CA (1) CA2690856C (zh)
CL (1) CL2008001667A1 (zh)
CO (1) CO6251287A2 (zh)
CY (2) CY1113422T1 (zh)
DK (2) DK2444399T3 (zh)
EC (1) ECSP109856A (zh)
ES (2) ES2393425T7 (zh)
HK (2) HK1142318A1 (zh)
HR (2) HRP20120909T4 (zh)
IL (1) IL202158A (zh)
ME (1) ME01488B (zh)
MX (1) MX2009013078A (zh)
MY (1) MY158066A (zh)
NZ (1) NZ582445A (zh)
PE (1) PE20090328A1 (zh)
PL (2) PL2167502T6 (zh)
PT (2) PT2167502E (zh)
RS (2) RS53845B1 (zh)
RU (2) RU2470931C2 (zh)
SA (1) SA08290344B1 (zh)
SI (2) SI2444399T1 (zh)
TW (1) TWI417100B (zh)
UA (1) UA99129C2 (zh)
UY (1) UY31124A1 (zh)
WO (1) WO2008150233A1 (zh)
ZA (1) ZA200908285B (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
TW200804281A (en) * 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
KR20100065191A (ko) 2007-09-14 2010-06-15 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온
TW200927731A (en) 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
EA201001889A1 (ru) 2008-06-20 2011-08-30 Астразенека Аб Производные дибензотиазепина и их применение
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
BRPI0920354A2 (pt) 2008-10-16 2017-06-27 Addex Pharmaceuticals Sa derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5707390B2 (ja) 2009-05-12 2015-04-30 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
RS53075B (en) 2009-05-12 2014-04-30 Janssen Pharmaceuticals Inc. 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
RU2012134329A (ru) 2010-01-07 2014-02-20 Астразенека Аб Способ получения позитивного аллостерического модулятора метаботропных глутаматных рецепторов-874
AU2011245737A1 (en) * 2010-04-30 2012-12-20 Astrazeneca Ab Polymorphs of a metabotropic glutamate receptor positive allosteric modulator
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
DK3431106T3 (da) 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
JPWO2017014170A1 (ja) * 2015-07-17 2018-04-26 武田薬品工業株式会社 複素環化合物
EA033198B1 (ru) 2015-07-17 2019-09-30 Такеда Фармасьютикал Компани Лимитед Оксадиазольные производные, пригодные в качестве ингибиторов hdac
JPWO2017033946A1 (ja) 2015-08-25 2018-06-07 武田薬品工業株式会社 複素環化合物
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
BR112022000811A2 (pt) * 2019-07-18 2022-03-29 Abaxys Therapeutics Formulação sólida de um derivado de 1,2,4-oxadiazol
GB2621323A (en) * 2022-08-03 2024-02-14 Sirgartan Holdings Ltd Treatments for obsessive compulsive disorder

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (en) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. 3-methyleneisoindolin-1-one derivative
TW219935B (zh) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
RU2124511C1 (ru) * 1993-05-14 1999-01-10 Фармасьютикал Ко., Лтд Производные пиперазина
KR19990082330A (ko) 1996-02-06 1999-11-25 미즈노 마사루 신규 화합물 및 이의 의약 용도
US6417362B1 (en) 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
RU2257384C2 (ru) 2000-02-29 2005-07-27 Мицубиси Фарма Корпорейшн Новые производные циклического амида
MXPA03000923A (es) 2000-07-31 2003-06-09 Smithkline Beecham Plc Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
US20040242627A1 (en) * 2001-04-19 2004-12-02 Shuichi Suzuki 2-Iminoimidazole derivatives (1)
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
AR042139A1 (es) * 2002-11-26 2005-06-08 Maruishi Pharma Derivados de isoindolina, composicion farmaceutica que los contiene, y uso
AU2004226450A1 (en) 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
JP2007510629A (ja) 2003-10-22 2007-04-26 イーライ リリー アンド カンパニー 新規ｍｃｈ受容体アンタゴニスト
EP1713775A4 (en) 2004-01-30 2009-08-12 Smithkline Beecham Corp CHEMICAL COMPOUNDS
DE602005008558D1 (de) * 2004-02-18 2008-09-11 Astrazeneca Ab Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
AU2005219791B2 (en) 2004-03-05 2011-06-09 Msd K.K. Diaryl-substituted five-membered heterocycle derivative
ES2526614T3 (es) 2004-03-05 2015-01-13 Nissan Chemical Industries, Ltd. Compuesto de benzamida sustituida con isoxazolina y agente de control de organismos nocivos
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
US7960417B2 (en) 2005-02-24 2011-06-14 Merck Sharp & Dohme Corp. Benzazole potentiators of metabotropic glutamate receptors
NZ564254A (en) * 2005-05-18 2011-04-29 Addex Pharma Sa Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
CN101309905A (zh) * 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
ATE463495T1 (de) * 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Also Published As

Publication number Publication date
EP2167502A4 (en) 2011-04-06
MY158066A (en) 2016-08-30
EP2167502A1 (en) 2010-03-31
CA2690856C (en) 2015-12-15
RS52526B2 (sr) 2018-06-29
SA08290344B1 (ar) 2011-10-03
KR20100017640A (ko) 2010-02-16
UA99129C2 (ru) 2012-07-25
EP2167502B1 (en) 2012-09-19
CN101679403B (zh) 2013-01-02
CN101679403A (zh) 2010-03-24
BRPI0812889A2 (pt) 2017-05-23
CL2008001667A1 (es) 2009-03-06
HRP20120909T1 (en) 2012-12-31
PT2167502E (pt) 2012-11-26
ZA200908285B (en) 2010-08-25
DK2167502T3 (da) 2012-12-03
HRP20120909T4 (hr) 2013-11-08
EP2167502B3 (en) 2013-07-10
AU2008260717B2 (en) 2012-01-19
PE20090328A1 (es) 2009-04-24
PL2167502T6 (pl) 2013-12-31
WO2008150233A1 (en) 2008-12-11
US20080306077A1 (en) 2008-12-11
US8377940B2 (en) 2013-02-19
RU2009147708A (ru) 2011-07-20
IL202158A (en) 2015-11-30
KR20150116907A (ko) 2015-10-16
UY31124A1 (es) 2009-01-30
PT2444399E (pt) 2015-03-04
HK1142318A1 (en) 2010-12-03
JP5815644B2 (ja) 2015-11-17
RU2470931C2 (ru) 2012-12-27
ES2393425T7 (es) 2013-11-22
RS52526B (en) 2013-04-30
AR066882A1 (es) 2009-09-16
SI2167502T1 (sl) 2012-12-31
CN102977086B (zh) 2015-04-01
RS53845B1 (en) 2015-08-31
MX2009013078A (es) 2010-01-15
US20100267740A1 (en) 2010-10-21
AU2008260717A1 (en) 2008-12-11
TW200911254A (en) 2009-03-16
CY1116150T1 (el) 2017-02-08
ES2393425T3 (es) 2012-12-21
IL202158A0 (en) 2010-06-16
SI2444399T1 (sl) 2015-03-31
JP2014055164A (ja) 2014-03-27
TWI417100B (zh) 2013-12-01
CO6251287A2 (es) 2011-02-21
DK2444399T3 (en) 2015-03-02
HRP20150210T1 (en) 2015-06-05
JP5416696B2 (ja) 2014-02-12
CA2690856A1 (en) 2008-12-11
CY1113422T1 (el) 2016-06-22
PL2444399T3 (pl) 2015-04-30
ME01488B (me) 2014-04-20
PL2167502T3 (pl) 2013-01-31
EP2444399A1 (en) 2012-04-25
CN102977086A (zh) 2013-03-20
JP2010529118A (ja) 2010-08-26
ECSP109856A (es) 2010-02-26
EP2444399B1 (en) 2014-11-26
ES2531443T3 (es) 2015-03-16
RU2012141706A (ru) 2014-03-27
US8377939B2 (en) 2013-02-19
NZ582445A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
HK1166978A1 (zh) 噁二唑衍生物配體及其作為親代謝性谷氨酸受體 增效劑的用途
HK1155744A1 (zh) 異噁唑衍生物及其作為親代謝性谷氨酸受體增效劑的用途
EP2167501A4 (en) OXADIAZOLE LIGANDS FROM METABOTROPIC GLUTAMATE RECEPTORS AND THEIR USE AS POTENTIALIZERS - 841
IL213168A0 (en) 1,2,4-oxadiazole derivatives and their therapeutic use
IL202826A0 (en) New compounds and their uses 708
AP2011005613A0 (en) Heteroaryls amide derivatives and their use as glucokinase activators.
EP2200613A4 (en) PINEZIN DERIVATIVES AND USES THEREOF
EP1951680A4 (en) NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE
EP2124558A4 (en) SUBSTITUTED 1, 3-DIOXANES AND THEIR USE
GB0713259D0 (en) Pyrazine derivatives 954
EP2123644A4 (en) BENZOXAZEPINE DERIVATIVES AND THEIR USE
ZA201000107B (en) Pyrimidine derivatives 934
EP1991233A4 (en) Hydroxypiperidine derivatives and their use
IL201015A0 (en) New compounds and their uses 707
IL195430A0 (en) Arylsulfonamidyl tetralin derivatives and uses thereof
ZA200900960B (en) Arylpiperazine derivatives and uses thereof
ZA200810629B (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
IL196823A0 (en) Tetraarylporphine derivatives and uses thereof
IL200457A0 (en) Isoflavone derivatives and uses thereof
IL204617A0 (en) N-phenyl anthranilic acid derivatives and uses thereof
ZA200906673B (en) New compounds and their uses 707
GB0613709D0 (en) Biocyclo[2.2.1]hept-7-ylamine derivatives and their uses
SI2013191T1 (sl) 3,7-diamino-10H-fenotiazinske soli in njihova uporaba
GB0618761D0 (en) Derivatives 2
PL379610A1 (pl) Nowe S-mono- i S2,S5-dipodstawione pochodne 2,5-dimerkapto-1,3,4-tiodiazolu, sposób ich wytwarzania oraz zastosowanie

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190531